Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Quentis Therapeutics

Request full access

Quentis Therapeutics a biotechnology company

New York City, United StatesFounded 2016Biotech & Life Sciences

About Quentis Therapeutics

Quentis Therapeutics, founded in 2016 by Juan Cubillos-Ruiz and Sarah Bettigole, was a biotechnology company focused on developing therapies for cancer and neurodegenerative diseases. The company's scientific basis stemmed from research at Weill Cornell Medicine by Laurie Glimcher, M.D., and co-founder Juan Cubillos-Ruiz, Ph.D., which identified the crucial role of the endoplasmic reticulum (ER) stress response in compromising the immune system's ability to combat cancer. This research indicated that chronic activation of ER stress is linked to poor outcomes in various cancers, including ovarian, triple-negative breast, pancreatic, and glioblastoma.

The company's primary business was the research and development of cancer immunotherapies designed to modulate these ER stress response pathways within the tumor microenvironment. By doing so, Quentis aimed to enhance a patient's own anti-tumor immunity. The business model was centered on advancing its therapeutic candidates through preclinical and clinical trials to eventually secure regulatory approval and commercialize them. The company's lead product candidate was a first-in-class small molecule inhibitor of the inositol-requiring enzyme 1 α (IRE1α). This enzyme is a central component in the ER stress-response signaling pathway, and inhibiting it was intended to reduce ER stress and boost anti-tumor immunity.

Quentis secured significant funding to advance its pipeline, raising a total of $51 million over three rounds. This included a $48 million Series A financing in February 2018, co-led by Versant Ventures and Polaris Partners, with participation from AbbVie Ventures, Taiho Pharmaceutical, and others. These funds were allocated to advance the lead IRE1α inhibitor program into the clinic in 2019, develop a pipeline of preclinical programs, and expand the team. Despite its promising start and being named one of Fierce Biotech's "Fierce 15" of 2018, Quentis Therapeutics is no longer active and is considered a deadpooled company as of March 2022.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Dec 2018 $1M — Undisclosed —
SERIES AOther financing Feb 2018 $48M $192M Abbvie Biotech Ventures · Polaris Partners · Alexandria Venture Investments · Yonghua Capital —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Quentis Therapeutics website traffic

Latest recorded traffic for Quentis Therapeutics is 80 monthly website visits, down 83.3% over the last three months.

Latest monthly visits80 3-month web change-83.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Quentis Therapeutics in the New York City ecosystem

Live from Dealroom

The Quentis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors1 additional known investor

  • MD Anderson Cancer Center
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Quentis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Quentis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.